Immunocore Holdings plc (NASDAQ:IMCR) Shares Acquired by HealthInvest Partners AB

HealthInvest Partners AB grew its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 127.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 54,060 shares of the company’s stock after acquiring an additional 30,282 shares during the period. Immunocore comprises about 0.8% of HealthInvest Partners AB’s portfolio, making the stock its 27th largest holding. HealthInvest Partners AB owned 0.11% of Immunocore worth $1,683,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Janus Henderson Group PLC increased its stake in shares of Immunocore by 45.8% during the 1st quarter. Janus Henderson Group PLC now owns 257,080 shares of the company’s stock worth $16,711,000 after purchasing an additional 80,748 shares during the last quarter. Tidal Investments LLC acquired a new position in shares of Immunocore during the 1st quarter worth about $423,000. DNB Asset Management AS raised its position in shares of Immunocore by 35.0% during the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after purchasing an additional 1,868 shares during the period. SG Americas Securities LLC grew its holdings in shares of Immunocore by 1,867.3% during the second quarter. SG Americas Securities LLC now owns 160,358 shares of the company’s stock worth $5,435,000 after buying an additional 152,207 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. increased its stake in Immunocore by 6.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 22,622 shares of the company’s stock valued at $767,000 after buying an additional 1,390 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Analyst Ratings Changes

IMCR has been the topic of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. Morgan Stanley lowered their price target on shares of Immunocore from $80.00 to $74.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Needham & Company LLC decreased their target price on Immunocore from $78.00 to $71.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Barclays dropped their price target on Immunocore from $92.00 to $66.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $69.18.

Immunocore Trading Down 0.5 %

Shares of IMCR stock traded down $0.16 during trading hours on Thursday, hitting $32.26. 4,178 shares of the company were exchanged, compared to its average volume of 513,782. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore Holdings plc has a fifty-two week low of $29.72 and a fifty-two week high of $76.98. The company has a 50 day simple moving average of $32.34 and a two-hundred day simple moving average of $37.94.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.50. The firm had revenue of $80.25 million during the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business’s revenue was up 23.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.59) earnings per share. On average, research analysts forecast that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.